PLX logo

PROTALIX BIOTHERAPEUTICS INC

PLXNYSE AMERICAN
🏆 #3568 by market capEarnings Nov 16US Equity
$2.61▲ $0.02 (+0.77%)
Market closed · at close
🔔
Track PLX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.8%
7d▲ 2.4%
14d▼ 0.2%
30d▼ 5.3%
ytd▲ 45.4%
1y▲ 15.0%
🏦Market Cap
$210M
Small Cap
📈Revenue Growth (YoY)
30.1%
High Growth
📊Gross Margin
69.2%
High
💵FCF Margin
28.4%
Strong
⚖️P/S Ratio
2.6x
Cheap
Otter Score
92
Excellent

Trading Snapshot

Day Range
$2.60 – $2.67
52-Week Range
$1.65 – $3.19
Volume (shares)
16,783
Avg Volume (shares)
—
Shares Outstanding
80.6M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
11.2
P/S Ratio
2.6x
EPS (TTM)
$0.23
Dividend Yield
—
Dilution (1yr)
−3.1%
PLX logo

PROTALIX BIOTHERAPEUTICS INC

PLX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$53M▼ −1.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
47.8%▼ −12.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −240.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▼ −284.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
78.5M▼ −3.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▼ −$8M YoY
StockOtter · stockotter.space

About PROTALIX BIOTHERAPEUTICS INC

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Excellent
92/100

Analyst Ratings

ⓘ
Consensus
Buy
5 analysts
Strong Buy1
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.